NEW YORK, Oct. 10, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links provided. There is no cost or obligation to you.
AbbVie Inc. (NYSE: ABBV)
Class Period: October 25, 2013 - September 18, 2018
Lead Plaintiff Deadline: November 20, 2018
Join the action: https://www.zlk.com/pslra-1/abbvie-inc-loss-form?wire=3
About the lawsuit: Throughout the class period, AbbVie Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) AbbVie’s strategy to increase the sales growth of its blockbuster drug, HUMIRA, was through illegal kickbacks and unlawful sales and marketing tactics; (2) such practices would lead to heightened scrutiny by State governments and agencies; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.
To learn more about the AbbVie Inc. class action contact jlevi@levikorsinsky.com.
Alnylam Pharmaceuticals, Inc. (NASDAQGS: ALNY)
Class Period: February 15, 2018 - September 12, 2018
Lead Plaintiff Deadline: November 26, 2018
Join the action: https://www.zlk.com/pslra-1/alnylam-pharmaceuticals-inc-loss-form?wire=3
About the lawsuit: During the class period, Alnylam Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Alnylam overstated the efficacy and safety of its Onpattro (patisiran) lipid complex injection; and (2) as a result, Alnylam’s public statements were materially false and misleading at all relevant times.
To learn more about the Alnylam Pharmaceuticals, Inc. class action contact jlevi@levikorsinsky.com.
Adient plc (NYSE: ADNT)
Class Period: October 31, 2016 - June 11, 2018
Lead Plaintiff Deadline: December 3, 2018
Join the action: https://www.zlk.com/pslra-1/adient-plc-loss-form?wire=3
The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements. In particular, the complaint alleges that defendants repeatedly stressed to investors that the Company was “solidly on track” to deliver 200-basis-point margin expansion by 2020, which was largely dependent on operational and financial improvements in Adient’s core SS&M business, while unbeknownst to investors, Adient’s core SS&M business faced significant operational problems such that the repeatedly touted 200-basis-point margin expansion was not “on track” at any point during the Class Period. Consequently, Adient stock traded at artificially inflated prices during the Class Period, reaching a high of $85.93 per share.
To learn more about the Adient plc class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com